Effect of Septal Versus Apical Pacing- a Comparative Study Using Cardiac MRI
MAPS
Multiparametric CMR Assessment of Apical Versus Septal Pacing Study
1 other identifier
interventional
53
1 country
1
Brief Summary
Despite considerable effort the optimal site to place a pacemaker lead at the time of pacemaker implant remains unclear. Historically pacemaker leads have always been inserted at the bottom (apex) of the heart. It is suggested that a lead placed at the apex is associated with an increase in heart rhythm problems and also heart failure (impaired pumping function). The top of the ventricle (septum) has been investigated as an alternative site and is now routinely used by some centres. Previous estimation of the hearts pumping function (ejection fraction) has been limited to the use of echo (sound waves). Echo is not sensitive enough to detect small changes in the ejection fraction reliably (measure of pumping function of heart). The gold standard for measurement of ejection fraction is MRI (using magnets). Previous pacemakers have not been compatible with MRI scans. The latest generation of pacemakers are now able to be safely scanned within an MRI scanner. This allows a much more accurate estimation of the effects of a pacemaker on the ejection fraction which has not yet been studied. The investigators plan to study those patients undergoing a pacemaker implant and ablation procedure as part of their standard care. Individuals will have an exercise test, blood test used to measure biomarkers and fill in a symptom questionnaire. Individuals will have a Cardiac MR compatible pacemaker fitted and 2 ventricular leads will be inserted, one apically and one septally. Only one lead will be used at any given time. Individuals will then undergo their planned AV node ablation. Following this they will have a cardiac MR scan. Further MRI scans will be performed at 9 and 18 month intervals, as will symptom questionnaires, blood tests (BNP) to determine heart muscle strain, exercise testing and echocardiograms. The hypothesis is that a lead placed on the septum will produce superior cardiac performance over the short and long term.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Feb 2012
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2012
CompletedFirst Submitted
Initial submission to the registry
April 24, 2013
CompletedFirst Posted
Study publicly available on registry
April 29, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2015
CompletedFebruary 4, 2019
January 1, 2013
3.9 years
April 24, 2013
February 1, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Ventricular Ejection fraction
Comparison of % change in Left and Right Ventricular Ejection Fractions between apical and septal pacing groups as measured on MRI.
18 months
Secondary Outcomes (12)
Levels of BNP
18 months
MRI measures of Left and Right ventricular dyssynchrony
18 months
Exercise Capacity as measured by CPEX
18 months
6 minute walk tests
18 months
Quality of life measures SF36
18 months
- +7 more secondary outcomes
Study Arms (2)
Apical Pacing
ACTIVE COMPARATORPacemaker programmed to pacing the heart at apex for 9 months.
Septal Pacing
ACTIVE COMPARATORPacemaker programmed to pacing the heart at the septum for 9 months.
Interventions
Pacemaker set to pace at right ventricular apex initially.
Pacemaker set to pace at right ventricular septum initially.
MR conditional Pacemaker implanted in all study patients
Eligibility Criteria
You may qualify if:
- Patients in permanent Atrial Fibrillation (AF)requiring a pacemaker on clinical grounds (tachycardia/bradycardia syndrome or requiring an AV node ablation)and AV node ablation or a pacemaker for rate control)
- Patients aged 18 to 85 years old.
- Able to consent for study.
You may not qualify if:
- Patients with moderate to severe LV dysfunction (EF \< 40%).
- Any contraindication to an MRI scan.
- Patients indicated for an Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy.
- Patients with a Myocardial Infarction within three months prior to enrollment.
- Patients that received bypass surgery within three months prior to enrollment.
- Patients that had a valve replacement within three months prior to enrollment or patients with a mechanical right heart valve.
- Patients where a right ventricular lead cannot be placed e.g. complex congenital heart disease.
- Patients with hypertrophic obstructive cardiomyopathy.
- Patients with acute coronary syndrome, unstable angina, severe mitral regurgitation and/or haemodynamically significant aortic stenosis.
- Previous implanted pacemaker or cardioverter defibrillator.
- Terminal conditions with a life expectancy of less than two years.
- Participation in any other study that would confound the results of this study.
- Psychological or emotional problems that may interfere with the volunteer's ability to provide full consent or fully understand the purposes of the study.
- Pregnant patients or patients who may become pregnant during the time-scale of the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Manchester University NHS Foundation Trustlead
- Abbott Medical Devicescollaborator
- British Heart Foundationcollaborator
Study Sites (1)
University Hospital of South Manchester NHS trust
Manchester, M23 9LT, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mark Dr Ainslie, MBChB
University Hospital of South Manchester
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- DIAGNOSTIC
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 24, 2013
First Posted
April 29, 2013
Study Start
February 1, 2012
Primary Completion
December 31, 2015
Study Completion
December 31, 2015
Last Updated
February 4, 2019
Record last verified: 2013-01